Olaugh123...Pfizer paid $6 billion for Arena Pharma in California with one clinical trial candidate utilizing cannabinoid compounds and that was not for an oncology application. Pfizer paid over $40 billion for Seagen, payload delivery and targeting mechanism for oncology application. Seagen does not develop the contents of the payload but Medipharm Labs does. Maybe you can now connect the logic between LABS saying they have over 20 strong clinical trials, many in late stage and having a large traditional global pharma partner.
Once the DEA reschedules, cannabinoids can now be commercialized for pharmaceutical applications.
Sometimes a large global company re-invents itself because of newer technologies and Pfizer is that company.